Astellas Pharma Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALPMY Over the counter 2834 www.astellas.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Astellas Pharma Inc.

Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock? - Jan 22nd, 2026 4:15 am
Has Astellas Pharma (TSE:4503) Run Too Far After Its 61% One Year Share Price Jump? - Jan 15th, 2026 10:09 pm
Ocular Launches, And Then Yo-Yoes, On Rumors Sanofi Is Preparing A Bigger Bid - Jan 15th, 2026 2:20 pm
VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses - Jan 8th, 2026 8:30 am
Pfizer, Astellas Report Positive Phase 3 Trial Results for PADCEV Combination in Bladder Cancer Treatment - Jan 8th, 2026 7:13 am
Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference - Jan 6th, 2026 4:30 pm
How Attractive Is Astellas Pharma After a 44.1% Surge and Mixed Valuation Signals? - Dec 22nd, 2025 3:07 pm
Positive Phase 3 PADCEV–Keytruda Bladder Cancer Data Could Be A Game Changer For Astellas Pharma (TSE:4503) - Dec 22nd, 2025 4:07 am
Reassessing Astellas Pharma (TSE:4503) Valuation After Positive PADCEV-Keytruda Phase 3 Bladder Cancer Results - Dec 21st, 2025 6:09 pm
PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility - Dec 17th, 2025 4:45 am
Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines - Dec 11th, 2025 5:30 am
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium - Dec 10th, 2025 4:30 pm
Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting - Dec 5th, 2025 6:00 am
Should FDA Approval of PADCEV-Keytruda Combo Shape the Outlook for Pfizer (PFE) Investors? - Nov 25th, 2025 1:11 am
Astellas Pharma (TSE:4503): Exploring Valuation After Strong 21% Monthly Share Price Rally - Nov 22nd, 2025 5:12 am
Sector Update: Health Care Stocks Higher Late Afternoon - Nov 21st, 2025 1:45 pm
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer - Nov 21st, 2025 11:24 am
Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3? - Nov 21st, 2025 8:30 am
Renal Anemia Market Research Report 2025-2035, Competitive Analysis of Amgen, Sandoz, Pfizer, GlaxoSmithKline, Akebia Therapeutics, and Astellas Pharma - Nov 18th, 2025 8:37 am
Bladder Cancer Market - Global and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson - Oct 30th, 2025 11:16 am